Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes

Table 2

Comparison of uric acid changes at baseline and after treatment.

Parameters	Group A^a		value^b	Group B^c		value^b	value^d
	Baseline	End point		Baseline	End point
Body weight in kg ()			0.005			0.02	0.001
BMI in kg/m^2 ()			0.001			0.056	0.002
Fasting blood glucose in mg/dl ()			0.42			0.042	0.62
Serum uric acid level in mg/dl ()			0.001			0.042	0.001

^aSGLT-2 inhibitors (): empagliflozin () and dapagliflozin (). ^bComparison within groups. ^cStandard OAD therapy (). ^dComparison of changes of each variable between the two groups. Abbreviations: BMI: body mass index; HbA1c: glycated hemoglobin; OAD: oral antihyperglycemic drug; SD: standard deviation; SGLT-2: sodium-glucose cotransporter-2.